Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Am J Psychiatry. 2018 Aug 29;175(12):1205–1215. doi: 10.1176/appi.ajp.2018.18020138

Figure 3. Time-course of HDRS6 and HDRS17 in an alternate patient grouping consistently demonstrates naltrexone block of ketamine’s antidepressant effect.

Figure 3.

A. Left, HDRS6 time-course (mean ± SD) in all patients who received both infusions in the crossed over design (N=12), including N=5 patients who did not meet the ketamine responsive criterion required for inclusion in our primary outcome analysis. A. Left, HDRS6 time-course. The difference between K+N versus K+P group scores on Day 1 after infusion is maintained with inclusion of ketamine non-responders in the cross-over analysis. Right, Box and whisker plot of the Day 0-to-Day 1 score changes for HDRS6 in each treatment condition for all crossed-over patients. (Horizontal line, median; “+”, mean; box, 25–75th percentile; whiskers, minimummaximum score). B. Left, HDRS17 time-course, demonstrating qualitatively similar results as in A. Right, Box and whisker plot for distribution of Day 0-to-Day 1 score changes for HDRS17 in each treatment condition, as in A.